A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

计划入组 12 人 · 首次发布于 2020 年 8 月 13 日

SARC021C: A Continuation Study of TH-CR-406/SARC021

首次发布于 2016 年 3 月 18 日

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

计划入组 51 人 · 首次发布于 2010 年 3 月 2 日

ST-406

ESG-406

CPC-406

AMARA VENTURES

India

Stoh Ventures, Inc.

United States

Endo Ventures Limited

United States

FamilyWell Health Secures $8M Series A to Expand Integrated Women's Mental Health Platform

Rectify Pharmaceuticals Reports Promising Preclinical Data for RTY-406 in Primary Sclerosing Cholangitis at EASL 2026

Rectify Pharmaceuticals Unveils RTY-406, an Oral Dual ABCB4/BSEP Modulator for Primary Sclerosing Cholangitis